Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics

@inproceedings{Bcps2010QuadrivalentHP,
  title={Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics},
  author={T. C. Pomfret PharmD Bcps and J. M. Gagnon Jr PharmD Bcps and A. T. Gilchrist PharmD Bcps},
  year={2010}
}
Summary What is known and background:  The introduction of vaccines has lead to a significant reduction in morbidity and mortality from diseases such as measles, rubella and poliomyelitis, as well as the eradication of smallpox (Ertl HC, Xiang Z (1996) The Journal of Immunology, 156, 3579–3582). A recent vaccine approved by the Food and Drug Administration (FDA) is the recombinant quadrivalent human papillomavirus (HPV) vaccine (Merck, Gardasil®). Concerns raised with this preventive measure… CONTINUE READING

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Increasing HPV Vaccination Rates Using Social Marketing Strategies

VIEW 6 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

[The human papillomavirus vaccine: some precisions].

  • Revista peruana de medicina experimental y salud publica
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED